Press Releases on January 8, 2024 - EIN Presswire - Press Release Distribution Service

Published on January 8, 2024 - 12:00 GMT

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and ...

Positive Phase 1 data presented at American Society of Hematology supports prioritizing the acceleration of enrollment of NX-5948 in leukemia and lymphoma Strategic collaborations in small molecule, targeted protein degradation with Gilead and Sanofi, and …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on January 8, 2024 - 12:00 GMT

Dave Ramsey Hosts Break the Cycle: Stop Living Paycheck to Paycheck Free Livestream Event January 11

Nashville, Tenn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Research indicates a full two-thirds of Americans feel trapped in a vicious cycle of financial mistakes, but it doesn’t have to be this way. In fact, a recent study by Ramsey Solutions found that 90% of …

Distribution channels: Media, Advertising & PR ...

Published on January 8, 2024 - 12:00 GMT

Abercrombie & Fitch Co. Increases Fourth Quarter Sales and Operating Margin Outlook Based on Better-Than-Expected Holiday Sales

NEW ALBANY, Ohio, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Abercrombie & Fitch Co. (NYSE: ANF) today provided a business update, increasing its net sales and operating margin outlook for fourth quarter and full year of fiscal 2023. Fran Horowitz, Chief …

Distribution channels: Media, Advertising & PR, Textiles & Fabric Industry ...

Published on January 8, 2024 - 12:00 GMT

Akoustis to Attend the 26th Annual Needham Growth Conference on January 16, 2024

Charlotte, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless …

Distribution channels:

Published on January 8, 2024 - 12:00 GMT

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy ...

- Preliminary data from the 5 mg/kg PGN-EDO51 dose level in the CONNECT1-EDO51 Phase 2 trial are expected mid-2024: including initial safety, exon 51 skipping and dystrophin protein production data - - Phase 1 results following a single dose of 10 mg/kg of …

Distribution channels: Media, Advertising & PR, Technology ...

Published on January 8, 2024 - 12:00 GMT

Collective Metals Announces Results of Phase II Soil Geochemical Sampling Program on its Princeton Project

Highlights Company has received final assays from Phase II of its two-phase 2023 soil-sampling program Phase II Program extends two multi-element (Cu-Ag-Au-Te) anomalies with coincident chargeability highs identified along Trojan-Condor Corridor in Phase I …

Distribution channels: Banking, Finance & Investment Industry, Mining Industry ...

Published on January 8, 2024 - 12:00 GMT

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and Chengdu Kanghua Biological Products Co., Ltd. (Kangh) (SHE: …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on January 8, 2024 - 12:00 GMT

CRAWFORD UNITED ACQUIRES HEANY INDUSTRIES

CLEVELAND, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Crawford United Corporation (OTC: CRAWA) today announced the purchase of Heany Industries effective January 2, 2024. Founded in 1932, Heany Industries is located in Scottsville, New York. Heany Industries …

Distribution channels: Media, Advertising & PR ...

Published on January 8, 2024 - 12:00 GMT

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Adenosine portfolio clinical data readouts anticipated in second half of 2024, including inupadenant’s …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on January 8, 2024 - 12:00 GMT

Option Care Health Selects Palantir’s Artificial Intelligence Platform for Enterprise-Wide Digital Transformation

DENVER and BANNOCKBURN, Ill., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Palantir Technologies Inc. (NYSE: PLTR), a leading provider of AI systems, and Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider …

Distribution channels: Business & Economy, Companies ...

Published on January 8, 2024 - 12:00 GMT

Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis

– Second and third FDA Fast Track Designations for CABA-201, following the systemic lupus erythematosus (SLE) and lupus nephritis (LN) designation, providing the opportunity for expedited development and review of CABA-201 for the treatment of these …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on January 8, 2024 - 12:00 GMT

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

- FHD-286 combination study in AML continues to progress in the clinic with data anticipated in the second half of 2024; preclinical combination data with FHD-286 and tyrosine kinase inhibitors (TKIs) in EGFR/KRAS resistance anticipated by the second …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on January 8, 2024 - 12:00 GMT

Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J....

Preclinical data support profile for development of a potential best-in-class drug IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after VANCOUVER, Wash. and NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Absci Corporation ( …

Distribution channels:

Published on January 8, 2024 - 12:00 GMT

Destination XL Group, Inc. Reports Holiday Sales Results

CANTON, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (NASDAQ: DXLG), the leading integrated-commerce specialty retailer of Big + Tall men’s clothing and shoes, today announced the following results for the 9-week holiday sales period …

Distribution channels: Media, Advertising & PR, Textiles & Fabric Industry ...

Published on January 8, 2024 - 12:00 GMT

Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 ...

-- Approximately $19 million and $28 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter and full year 2023, respectively -- -- Generated continued robust demand for LUMRYZ with greater than 1,900 patients enrolled in RYZUPTM and …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on January 8, 2024 - 12:00 GMT

iTeos kündigt strategische Prioritäten für 2024 und voraussichtliche Meilensteine an

- Klinische Daten aus dem TIGIT-Programm werden für 2024 erwartet, darunter zwei Phase-II-Studien zur Bewertung von Belrestotug + Dostarlimab bei NSCLC und HNSCC in der Erstlinie - Klinische Daten aus dem Adenosin-Portfolio werden in der zweiten …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on January 8, 2024 - 12:00 GMT

iTeos annonce ses priorités stratégiques et les étapes importantes attendues en 2024

- Les extractions de données cliniques issues du programme TIGIT attendues en 2024, dont deux essais de Phase II évaluant belrestotug + dostarlimab dans le CPNPC en 1re ligne et le CETC en 1re ligne - Les extractions de données cliniques issues du …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on January 8, 2024 - 12:00 GMT

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous ...

Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026 Alignment has been reached with the FDA on the clinical …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on January 8, 2024 - 12:00 GMT

Be The Match® Affirms Global Leadership in Life-saving Cell Therapies with New Name, Brand: NMDP℠

MINNEAPOLIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- National Marrow Donor Program®/Be The Match®, which operates the world’s most diverse registry of blood stem cell and marrow donors, is proud to unveil its new organizational name and brand: NMDP℠. Find cures. …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on January 8, 2024 - 12:00 GMT

Solaris Provides 2024 Preview Including Planned NYSE American Listing and Updated Warintza Mineral Resource Estimate in Q2/24

VANCOUVER, British Columbia, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce a preview of its 2024 plans for the Company and its Warintza Project (“Warintza” or “the …

Distribution channels: Banking, Finance & Investment Industry, Mining Industry ...